Rekovelle

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IA/0039	A.7 - Administrative change - Deletion of manufacturing sites	28/08/2023	n/a		
IA/0040	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect	16/08/2023	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	the product information				
II/0037/G	This was an application for a group of variations. Grouped application comprising two type II variations as follows: - Update of sections 4.1, 4.2, 4.4, 4.5 and 5.1 of the SmPC to update the safety information following final results from study 000304 (BEYOND). This is a randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol and a GnRH antagonist protocol in women undergoing controlled ovarian stimulation. - Update of section 4.8 of the SmPC, including the tabulation of adverse drug reactions based on pooled safety data from studies ESTHER-1, ESTHER-2, 000273, 000145, BEYOND and RAINBOW. The updated RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	20/07/2023		SmPC and PL	The BEYOND trial provided efficacy and safety information about the use of follitropin delta (REKOVELLE) within a GnRH agonist protocol, as this was not studied at the time of the marketing authorisation application, but it is still used in clinical practice. Pooled data from BEYOND and other clinical trials did not identify new safety information. The subset of women with AMH ≥ 35 pmol/L have not been studied in a GnRH agonist protocol, as reflected in the updated section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics.

IB/0038	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	14/03/2023	n/a		
IA/0036	A.7 - Administrative change - Deletion of manufacturing sites	19/01/2023	n/a		
II/0034	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	24/11/2022	n/a		
IB/0035/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	15/09/2022	n/a		
IB/0033	B.IV.1.z - Change of a measuring or administration device - Other variation	17/05/2022	n/a		
IAIN/0032	A.1 - Administrative change - Change in the name and/or address of the MAH	25/03/2022	31/05/2023	SmPC, Annex II, Labelling and PL	
II/0030	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	17/02/2022	n/a		

IAIN/0031	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	27/01/2022	n/a		
R/0028	Renewal of the marketing authorisation.	20/05/2021	16/07/2021	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rekovelle in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
PSUSA/10554 /202011	Periodic Safety Update EU Single assessment - follitropin delta	08/07/2021	n/a		PRAC Recommendation - maintenance
II/0023	Update of section 5.1 of the SmPC in order to add information on dose equivalence factor to follitropin alfa based on clinical data from literature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	18/03/2021	16/07/2021	SmPC	
IA/0029	A.7 - Administrative change - Deletion of manufacturing sites	11/02/2021	16/07/2021	Annex II and PL	
IB/0026	B.IV.z - Quality change - Change in Medical Devices - Other variation	21/01/2021	n/a		
II/0022	Update of section 4.2 of the SmPC in order to introduce new anti-Müllerian hormone (AMH) assays to determine the dose of follitropin delta, following an agreed recommendation. In consequence, RMP	14/01/2021	16/07/2021	SmPC	The MAH proposed AMH tests to be used to determine the dose of follitropin delta, in addition to the currently mentioned immunoassay in the SmPC section 4.2. For more information, please refer to the Summary of

	version 5.0 was submitted and updated in line with GPV Module V rev.2. The MAH took the opportunity to amend section 4.4. of the SmPC with traceability information, to bring the PI in line with the latest QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				Product Characteristics.
IB/0025	B.IV.1.z - Change of a measuring or administration device - Other variation	16/12/2020	16/07/2021	SmPC, Annex II, Labelling and PL	
IB/0024	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	30/09/2020	n/a		
PSUSA/10554 /201911	Periodic Safety Update EU Single assessment - follitropin delta	09/07/2020	n/a		PRAC Recommendation - maintenance
IAIN/0021/G	This was an application for a group of variations. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.b - Change of a measuring or administration device - Deletion of a device	10/04/2020	n/a		
PSUSA/10554 /201811	Periodic Safety Update EU Single assessment - follitropin delta	14/06/2019	n/a		PRAC Recommendation - maintenance

IB/0017	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	29/04/2019	n/a		
IAIN/0019	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	10/04/2019	n/a		
IB/0018	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	01/04/2019	n/a		
IB/0015	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	14/02/2019	n/a		
IB/0013	B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing	08/02/2019	n/a		
PSUSA/10554 /201805	Periodic Safety Update EU Single assessment - follitropin delta	17/01/2019	n/a		PRAC Recommendation - maintenance
IA/0014	A.7 - Administrative change - Deletion of manufacturing sites	11/01/2019	n/a		
IB/0012	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement	28/11/2018	n/a		

	or addition) for the AS or a starting material/intermediate				
II/0008/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	13/09/2018	n/a		
IA/0010	A.7 - Administrative change - Deletion of manufacturing sites	28/06/2018	n/a		
PSUSA/10554 /201711	Periodic Safety Update EU Single assessment - follitropin delta	14/06/2018	n/a		PRAC Recommendation - maintenance
IA/0009	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	09/05/2018	n/a		
PSUSA/10554 /201705	Periodic Safety Update EU Single assessment - follitropin delta	11/01/2018	n/a		PRAC Recommendation - maintenance
IB/0006	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	14/12/2017	n/a		

IB/0004/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	14/06/2017	n/a		
II/0003/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.IV.1.c - Change of a measuring or administration	18/05/2017	08/05/2018	SmPC, Annex II, Labelling and PL	

	device - Addition or replacement of a device which is an integrated part of the primary packaging				
IB/0002	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	01/02/2017	n/a		
IB/0001	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	30/01/2017	n/a		